id: opioid_use_disorder_to_smoking_current
name: Opioid Use Disorder â†’ Current Smoking Status
from_node:
  node_id: opioid_use_disorder
  node_name: Opioid Use Disorder
to_node:
  node_id: smoking_current
  node_name: Current Smoking Status
direction: positive
category: behavioral
mechanism_pathway:
- 'Step 1: Patients receiving opioid agonist therapy have extremely high tobacco smoking prevalence (85%)'
- 'Step 2: Concurrent substance use disorders create neurobiological vulnerabilities that reinforce tobacco
  dependence'
- 'Step 3: Treatment settings historically prioritize opioid treatment over tobacco cessation'
- 'Step 4: Current smoking cessation interventions show poor effectiveness (<10% quit rate) in this population'
- 'Step 5: Continued high smoking rates lead to disproportionate smoking-related pulmonary disease burden'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Karl Trygve Druckrey-Fiskaaen et al. 2025. "Multimethod feasibility evaluation of
    smoking cessation intervention for patients receiving opioid agonist therapy.." https://doi.org/10.1186/s40814-025-01717-2
  supporting_citations:
  - Additional citations require full-text access - 85% smoking prevalence cited from prior literature
  - Additional citations require full-text access - <10% quit rate with current interventions cited from
    prior literature
  - Additional citations require full-text access - significant impact of smoking-related pulmonary diseases
    on disability and mortality cited
  doi: 10.1186/s40814-025-01717-2
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Among patients receiving opioid agonist therapy, 85% are active tobacco smokers, representing
  a dramatically elevated prevalence compared to general population, contributing to significant pulmonary
  disease burden
quantitative_effects:
  effect_size:
    value: 85.0
    type: percentage_change
structural_competency:
  equity_implications: The co-occurrence of opioid use disorder and tobacco use reflects intersecting
    structural vulnerabilities including poverty, trauma, and inadequate integrated healthcare. Historical
    separation of substance use treatment from tobacco cessation services represents a structural failure
    that perpetuates health inequities. The population receiving OAT faces multiple marginalization including
    stigma and healthcare system fragmentation that compounds difficulty accessing effective smoking cessation
    support.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.193815'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
